Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

Inclusion Criteria:

• Male or female, 6 years or older at baseline visit (Canada has received thecountry's regulatory approval for use of Dupixent treating msAD for these ages).

• Participant is initiating dupilumab as part of routine clinical care through theDupixent Patient Support Program (PSP) for the treatment of msAD, as perreimbursement criteria. Decision to treat with dupilumab must have been reachedprior to and independently of recruitment in the study.

• Have a physician's diagnosis of msAD.

• Provided signed informed consent or parental/legally acceptable representativeconsent and/or participant assent. During the study, subjects will continue toreceive maintenance therapies for their AD as clinically indicated and as per usualmedical practice.

• Participant or Parental representative able to understand English and/or CanadianFrench to complete study-related questionnaires.

Exclusion Criteria:

• Participants who have a contraindication to the drug according to theCanadian-specific prescribing information label.

• Any condition that, in the opinion of the Investigator, may interfere withparticipant's ability to participate in the study, such as short life expectancy,substance abuse, severe cognitive impairment, or other comorbidities that canpredictably prevent the participant from adequately completing the schedule ofvisits and assessments.

• Participants currently participating in any interventional clinical trial whichmodifies participant care.

• Prior use of Dupixent within 6 months of the baseline visit.

• Participants not willing to sign the Informed Consent Form.